<DOC>
	<DOCNO>NCT01348022</DOCNO>
	<brief_summary>This study multicenter , open label , prospective , single arm trial Single arm group ; follow angiography , eligible patient unprotected LMCA stenosis &gt; 50 % visual estimation , equally treatable treatment strategy ( EES stenting CABG ) , treat EES</brief_summary>
	<brief_title>Evaluation Outcomes EES Implantation Unprotected Left Main Coronary Artery Stenosis ( PRE-COMBAT 2 )</brief_title>
	<detailed_description>The primary objective PRECOMBAT-2 trial establish safety effectiveness coronary stenting everolimus-eluting Xience V stent ( EES ) compare historical control ( PRE-COMBAT-1 ) bypass surgery sirolimus-eluting stent ( SES ) treatment unprotected LMCA stenosis . The primary alternative hypothesis experimental starategy ( coronary stenting everolimus-eluting stent ) inferior standard strategy ( CABG ) SES . All consecutive patient unprotected LMCA diseases participate center , treat Xience V stent , evaluate entry study .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<criteria>1 . The patient must least 18 year age . 2 . Significant de novo leave main stenosis ( &gt; 50 % visual estimation ) without additional target lesion ( &gt; 70 % visual estimation ) 3 . Left main lesion lesion outside LMCA ( present ) potentially equally treatable coronary stenting CABG 4 . Patients stable ( CCS class 1 4 ) acute coronary syndrome ( unstable angina pectoris Braunwald class IB , IC , IIB , IIC , IIIB , IIIC NSTEMI ) patient atypical chest pain without symptom document myocardial ischemia 5 . The patient guardian agrees study protocol schedule clinical angiographic followup , provide informed , write consent , approve appropriate Institutional Review Board/Ethical Committee respective clinical site . 1 . The patient know hypersensitivity contraindication follow medication : Heparin Aspirin Both Clopidogrel TIclopidine Everolimus , paclitaxel , ABT 578 Stainless steel and/or Contrast medium ( patient document sensitivity contrast effectively premedicated steroid diphenhydramine [ e.g . rash ] may enrol . Patients true anaphylaxis prior contrast medium , however , enrol ) . 2 . Systemic ( intravenous ) Everolimus , paclitaxel ABT578 use within 12 month . 3 . Any previous PCI within 1 year 4 . Previous bypass surgery 5 . Any previous PCI LMCA ostial leave circumflex artery ostial leave anterior descend artery lesion within 1 year 6 . Intention treat one totally occluded major epicardial vessel 7 . Acute MI patient within 1 week 8 . Patients EF &lt; 30 % . 9 . Patients cardiogenic shock 10 . Any disabled stroke neurological deficit cerebrovascular accident within 6 month 11 . Creatinine level 2.0mg/dL dependence dialysis . 12 . Severe hepatic dysfunction ( AST ALT 3 time upper normal reference value ) . 13 . Gastrointestinal genitourinary bleeding within prior 3 month , major surgery within 2 month . 14 . History bleed diathesis know coagulopathy ( include heparininduced thrombocytopenia ) , refuse blood transfusion . 15 . Current know current platelet count &lt; 100,000 cells/mm3 Hgb &lt; 10 g/dL . 16 . An elective surgical procedure plan would necessitate interruption thienopyridines first 1 year post enrollment . 17 . Noncardiac comorbid condition present life expectancy &lt; 1 year may result protocol noncompliance ( per site investigator 's medical judgment ) . 18 . Patients actively participate another drug device investigational study , complete primary endpoint followup period . 19 . Subject unable unwilling followup visit require protocol 20 . Female childbearing potential , unless recent pregnancy test negative , possibly plan become pregnant time enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>